Luteolin nanoparticle in chemoprevention: In vitro and in vivo anticancer activity

Cancer Prevention Research

Volumn 7, Issue 1, 2014, Pages 65-73

  Majumdar, Debatosh ^a   Jung, Kyung Ho ^a   Zhang, Hongzheng ^a   Nannapaneni, Sreenivas ^a   Wang, Xu ^a   Ruhul Amin, A R M ^a   Chen, Zhengjia ^a   Chen, Zhuo G ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; LUTEOLIN; MACROGOL; NANOPARTICLE; POLYLACTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG UPTAKE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; VEGETABLE;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOPREVENTION; DIET; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INHIBITORY CONCENTRATION 50; LUTEOLIN; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; POLYMERS; RHODAMINES; SOLUBILITY; VEGETABLES;

EID: 84892377192     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0230     Document Type: Article

References (65)

1. http://www.who.int/mediacentre/factsheets/fs297/en/
2. Hong WK, Sporn MB, Recent advances in chemoprevention of cancer. Science 1997;278: 1073-7.
3. Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009;27: 2712-25.
4. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21: 2895-900.
5. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001;19: 1830-8.
6. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 3808-14.
7. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009;2: 931-41.
8. Kandaswami C, Lee LT, Lee PP, Hwang JJ, KeFC, Huang YT, et al. The antitumor activities of flavonoids. In Vivo 2005;19: 895-909.
9. Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 2008;8: 634-46.
10. Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin Y. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated NF-kB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 2007;71: 1381-8.
11. Cai X, Ye T, Liu C, Lu W, Lu M, Zhang J, et al. Luteolin inducedG2phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol In Vitro 2011;25: 1385-91.
12. Lee HZ, Yang WH, Bao BY, Lo PL. Proteomic analysis reveals ATPdependent steps and chaperones involvement in luteolin-induced lung cancer CH27 cell apoptosis. Eur J Pharmacol 2010;642: 19-27.
13. Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 2008;87: 401-6.
14. Ong CS, Zhou J, Ong CN, Shen HM. Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3b-cyclin D1 pathway. Cancer Lett 2010;298: 167-75.
15. Amin AR, Wang D, Zhang H, Peng S, Shin HJ, Brandes JC, et al. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem 2010;285: 34557-65.
16. Zhang Q, Zhao XH, Wang ZJ. Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol 2008;46: 2042-53.
17. Lim do Y, Jeong Y, Tyner AL, Park JH. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 2007; 292:G66-75.
18. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 2006;66: 4826-34.
19. Chiu FL, Lin JK. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 2008;68: 61-71.
20. Zhou Q, Yan B, Hu X, Li XB, Zhang J, Fang J. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther 2009;8: 1684-91.
21. Fang J, Zhou Q, Shi XL, Jiang BH. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 2007;28: 713-23.
22. Wu B, Zhang Q, Shen W, Zhu J. Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Mol Cell Biochem 2008;313: 125-32.
23. Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, Gaben AM, et al. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol 2011;651: 18-25.
24. Manju V, Nalini N. Protective role of luteolin in 1,2-dimethylhydrazine induced experimental colon carcinogenesis. Cell Biochem Funct 2007;25: 189-94.
25. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol 2007;2: 203-4.
26. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2: 751-60.
27. LaVan DA, Lynn DM, Langer R. Moving smaller in drug discovery and delivery. Nat Rev Drug Discov 2002;1: 77-84.
28. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;21: 1184-91.
29. Moses MA, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 2003;4: 337-41.
30. Kawasaki ES, Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 2005;1: 101-9.
31. Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond) 2007;2: 669-80.
32. Wei C, Wei W, Morris M, Kondo E, Gorbounov M, Tomalia DA. Nanomedicine and drug delivery. Med Clin North Am 2007;91: 863-70.
33. Banerjee HN, Verma M. Application of nanotechnology in cancer. Technol Cancer Res Treat 2008;7: 149-54.
34. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target 2008;16: 108-23.
35. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63: 185-98.
36. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994;263: 1600-3.
37. Gref R, Minamitake Y, Peracchia MT, Domb A, Trubetskoy V, Torchilin V, et al. Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm Biotechnol 1997;10: 167-98.
38. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin- 3-gallate. Cancer Res 2009;69: 1712-6.
39. Sahu A, Bora U, Kasoju N, Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 2008;4: 1752-61.
40. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 2008;32: 1119-23.
41. Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Illum L, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm 2000;199: 95-110.
42. Yang ZL, Li XR, Yang KW, Liu Y. Amphotericin B-loaded poly(ethylene glycol)-poly(lactide) micelles: preparation, freeze-drying, and in vitro release. J Biomed Mater Res A 2008;85: 539-46.
43. Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, et al. b-Lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release 2007;122: 365-74.
44. Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, et al. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008;123: 1005-14.
45. Chen S, Cao W, Yue P, Hao C, Khuri FR, Sun S-Y. Celecoxib promotes c-FLIP degradation through AKt-independent inhibition of GSK3. Cancer Res 2011;7: 6270-81.
46. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1: 1112-6.
47. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5: 909-16.
48. Verma A, Uzun O, Hu Y, Hu Y, Han HS, Watson N, et al. Surfacestructure- regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater 2008;7: 588-95.
49. Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009;8: 543-57.
50. Wong-Ekkabut J, Baoukina S, Triampo W, Tang IM, Tieleman DP, Monticelli L. Computer simulation study of fullerene translocation through lipid membranes. Nat Nanotechnol 2008;3: 363-8.
51. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J 2004;377: 159-69.
52. Riley T, Govender T, Stolnik S, Xiong CD, Garnett MC, Illum L, et al. Colloidal stability and drug incorporation aspects ofmicellar-like PLAPEG nanoparticles. Colloids Surf B Biointerfaces 1999;16: 147-59.
53. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M, et al. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995;84: 493-8.
54. Tobío M, Sánchez A, Vila A, Soriano II, Evora C, Vila-Jato JL, et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEGPLA nanoparticles following oral administration. Colloids Surf B Biointerfaces 2000;18: 315-23.
55. Ueki K, Onishi H, Sasatsu M, Machida Y. Preparation of carboxy-PEGPLA nanoparticles loaded with camptothecin and their body distribution in solid tumor-bearing mice. Drug Dev Res 2009;70: 512-9.
56. Li Y, Qi XR, Maitani Y, Nagai T. PEG-PLA diblock copolymer micellelike nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations. Nanotechnology 2009;20: 2-11.
57. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995;84: 493-8.
58. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000;18: 301-13.
59. Miura H, Onishi H, Sasatsu M, Machida Y. Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin. J Control Release 2004;97: 101-13.
60. Nguyen CA, Allémann E, Schwach G, Doelker E, Gurny R. Cell interaction studies of PLA-MePEG nanoparticles. Int J Pharm 2003;254: 69-72.
61. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly (ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel antiglioblastoma effect. J Control Release 2010;143: 136-42.
62. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P. Stability study of nanoparticles of poly(epsilon-caprolactone), poly (D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials 1996;17: 2191-7.
63. Stefani M, Coudane J, Vert M. In vitro ageing and degradation of PEGPLA diblock copolymer-based nanoparticles. Polymer Degrad Stab 2006;91: 2554-9.
64. www.clinicaltrials.gov
65. Grandhi BK, Thakkar A, Wang J, Prabhu S. A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res 2013;6: 1015-25.